Moving toward a predictive and personalized clinical approach in amyotrophic lateral sclerosis: Novel developments and future directions in diagnosis, genetics, pathogenesis and therapies

EPMA Journal

Volumn 1, Issue 2, 2010, Pages 329-341

  Nefussy, Beatrice ^a,b   Drory, Vivian E ^a,b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Amyotrophic lateral sclerosis; Epidemiology; Genetics; Motor neuron disease; Neurodegeneration; Personalized treatment; Predictive diagnosis

Indexed keywords

ARIMOCLOMOL; BENZOTHIAZOLE; CEFTRIAXONE; COPPER ZINC SUPEROXIDE DISMUTASE; DEXTROMETHORPHAN; EXCITATORY AMINO ACID TRANSPORTER 2; FREE RADICAL; GLUTAMIC ACID; ISIS 333611; KNS 760704; NEUROPROTECTIVE AGENT; OLEXOSIME; PLACEBO; QUINIDINE; RILUZOLE; SB 509; TALAMPANEL; TAR DNA BINDING PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN A; ZENVIA;

AGE DISTRIBUTION; AMYOTROPHIC LATERAL SCLEROSIS; ASSISTED VENTILATION; CELL AGGREGATION; CLINICAL EXAMINATION; CLINICAL FEATURE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; ENTERIC FEEDING; EXCITOTOXICITY; FAMILIAL DISEASE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE LOCUS; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; INCIDENCE; KINESIOTHERAPY; MOLECULAR PATHOLOGY; MOTOR NEURON DISEASE; MUSCLE ATROPHY; MUSCLE WEAKNESS; NEUROIMAGING; NEUROPATHOLOGY; NONHUMAN; NUTRITIONAL SUPPORT; OXIDATIVE STRESS; PATIENT CARE; PERSONALIZED MEDICINE; PHYSICAL ACTIVITY; PHYSIOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; RISK FACTOR; RNA PROCESSING; SEX RATIO; STEM CELL TRANSPLANTATION; SURVIVAL RATE; VERBAL COMMUNICATION;

EID: 79953062539     PISSN: 18785077     EISSN: 18785085     Source Type: Journal    
DOI: 10.1007/s13167-010-0027-0     Document Type: Review

References (119)

1. van der Graaff MM, de Jong JM, Baas F, de Visser M. Upper motor neuron and extra-motor neuron involvement in amyotrophic lateral sclerosis: a clinical and brain imaging review. Neuromuscul Disord. 2009; 19: 53-8.
2. Qureshi M, Schoenfeld DA, Paliwal Y, Shui A, Cudkowicz M. The natural history of ALS is changing: improved survival. Amyotroph Later Scler. 2009; 10: 324-31.
3. Logroscino G, Traynor BJ, Hardiman O, Chio A, Mitchell D, Swingler RJ, et al. Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry. 2010; 81: 385-90.
4. Steele JC, McGeer PL. The ALS/PDC syndrome of Guam and the cycad hypothesis. Neurology. 2008; 70: 1984-90.
5. Kuzuhara S, Kokubo Y. Atypical parkinsonism of Japan: amyotrophic lateral sclerosis-parkinsonism-dementia complex of the Kii peninsula of Japan (Muro disease): an update. Mov Disord. 2005; 20: S108-13.
6. Worms PM. The epidemiology of motor neuron diseases: a review of recent studies. J Neurol Sci. 2001; 191: 3-9.
7. Zoccolella S, Beghi E, Palagano G, Fraddosio A, Guerra V, Samarelli V, et al. Analysis of survival and prognostic factors in amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry. 2008; 79: 33-7.
8. Sorenson EJ, Stalker AP, Kurland LT, Windebank AJ. Amyotrophic lateral sclerosis in Olmsted County, Minnesota, 1925-1998. Neurology. 2002; 59: 280-2.
9. Raaphorst J, de Visser M, Linssen WJP, de Haan R, Schmand B. The cognitive profile of amyotrophic lateral sclerosis: a meta-analysis. Amyotroph Later Scler. 2010; 11: 38-45.
10. Kurian KM, Forbes RB, Colville S, Swingler RJ. Cause of death and clinical grading criteria in a cohort of amyotrophic lateral sclerosis cases undergoing autopsy from the Scottish Motor Neurone Disease Register. J Neurol Neurosurg Psychiatry. 2009; 80: 84-7.
11. Zoccolella S, Beghi E, Palagano G, Fraddosio A, Guerra V, Samarelli V, et al. Predictors of long survival in amyotrophic lateral sclerosis: a population-based study. J Neurol Sci. 2008; 268: 28-32.
12. Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000; 1: 293-9.
13. Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman OM. Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House criteria: a population-based study. Arch Neurol. 2000; 57: 1171-6.
14. de Carvalho M, Dengler R, Eisen A, England JD, Kaji R, Kimura J, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol. 2008; 119: 497-503.
15. Zhang L, Ulug AM, Zimmerman RD, Lin MT, Rubin M, Beal MF. The diagnostic utility of FLAIR imaging in clinically verified amyotrophic lateral sclerosis. J Magn Reson Imaging. 2003; 17: 521-7.
16. Lule D, Ludolph AC, Kassubek J. MRI-based functional neuroimaging in ALS: an update. Amyotroph Lateral Scler. 2009; 10: 258-68.
17. Senda J, Ito M, Watanabe H, Atsuta N, Kawai Y, Katsuno M, et al. Correlation between pyramidal tract degeneration and widespread white matter involvement in amyotrophic lateral sclerosis: a study with tractography and diffusion-tensor imaging. Amyotroph Lateral Scler. 2009; 10: 288-94.
18. Dabby R, Lange DJ, Trojaborg W, Hays AP, Lovelace RE, Brannagan TH, et al. Inclusion body myositis mimicking motor neuron disease. Arch Neurol. 2001; 58: 1253-6.
19. Nobile-Orazio E, Carpo M, Meucci N. Are there immunologically treatable motor neuron diseases? Amyotroph Lateral Scler Other Motor Neuron Disord. 2001; 2: S23-30.
20. Parboosingh JS, Figlewicz DA, Krizus A, Meininger V, Azad NA, Newman DS, et al. Spinobulbar muscular atrophy can mimic ALS: the importance of genetic testing in male patients with atypical ALS. Neurology. 1997; 49: 568-72.
21. Drory VE, Birnbaum M, Peleg L, Goldman B, Korczyn AD. Hexosaminidase A deficiency is an uncommon cause of a syndrome mimicking amyotrophic lateral sclerosis. Muscle Nerve. 2003; 28: 109-12.
22. Tashiro K, Kikuchi S, Itoyama Y, Tokumaru Y, Sobue G, Mukai E, et al. Nationwide survey of juvenile muscular atrophy of distal upper extremity (Hirayama disease) in Japan. Amyotroph Lateral Scler. 2006; 7: 38-45.
23. Beleza-Meireles A, Al-Chalabi A. Genetic studies of amyotrophic lateral sclerosis: controversies and perspectives. Amyotroph Lateral Scler. 2009; 10: 1-14.
24. Dion PA, Daoud H, Rouleau GA. Genetics of motor neuron disorders: new insights into pathogenetic mechanisms. Nat Rev Genet. 2009; 10: 769-82.
25. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993; 362: 59-62.
26. Shaw PJ. Molecular and cellular pathways of neurodegeneration in motor neuron disease. J Neurol Neurosurg Psychiatry. 2005; 76: 1046-57.
27. Abe K, Aoki M, Ikeda M, Watanabe M, Hirai S, Itoyama Y. Clinical characteristics of familial amyotrophic lateral sclerosis with Cu/Zn superoxide dismutase gene mutations. J Neurol Sci. 1996; 136: 108-16.
28. Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006; 314: 130-3.
29. Mackenzie IR, Bigio EH, Ince PG, et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol. 2007; 61: 427-34.
30. Sreedharan J, Blair IP, Tripathi VB, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008; 319: 1668-72.
31. Yokoseki A, Shiga A, Tan CF, Tagawa A, Kaneko H, Koyama A, et al. TDP-43 mutation in familial amyotrophic lateral sclerosis. Ann Neurol. 2008; 63: 538-42.
32. Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, Velde C, et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet. 2008; 40: 572-4.
33. Wegorzewska I, Bell S, Cairns NJ, Miller TM, Baloh RH. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal degeneration. Proc Natl Acad Sci. 2009; 106: 18809-14.
34. Kwiatkowski Jr TJ, Bosco DA, Leclerc AL, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009; 323: 1205-8.
35. Vance C, Rogelj B, Hortobagyi T, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009; 323: 1208-11.
36. Belzil VV, Valdmanis PN, Dion PA, et al. Mutations in FUS cause FALS and SALS in French and French Canadian populations. Neurology. 2009; 73: 1176-9.
37. The International HapMap Consortium. A haplotype map of the human genome. Nature. 2005; 437: 1299-320.
38. Dunckley T, Huentelman MJ, Craig DW, Pearson JV, Szelinger S, Joshipura K, et al. Whole-genome analysis of sporadic amyotrophic lateral sclerosis. N Engl J Med. 2007; 357: 775-88.
39. van Es MA, Veldink JH, Saris CG, Blauw HM, van Vught PW, Birve A, et al. Genome-wide association study identifies 19p13. 3 (UNC13A) and 9p21. 2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat Genet. 2009; 41: 1083-7.
40. Blauw HM, Veldink JH, van Es MA, van Vught PW, Saris CG, van der Zwaag, et al. Copy-number variation in sporadic amyotrophic lateral sclerosis: a genome-wide screen. Lancet Neurol. 2008; 7: 319-26.
41. Chio A, Schymick JC, Restagno G, Scholz SW, Lombardo F, Lai SL, et al. A two-stage genome-wide association study of sporadic amyotrophic lateral sclerosis. Hum Mol Genet. 2009; 18: 1524-32.
42. Landers JE, Melki J, Meininger V, Glass JD, van den Berg LH, van Es MA, et al. Reduced expression of the Kinesin-associated protein 3 (KIFAP3) gene increases survival in sporadic amyotrophic lateral sclerosis. Proc Natl Acad Sci. 2009; 106: 9004-9.
43. Gros-Louis F, Andersen PM, Dupre N, Urushitani M, Dion P, Souchon F, et al. Chromogranin B P413L variant as risk factor and modifier of disease onset for amyotrophic lateral sclerosis. Proc Natl Acad Sci. 2009; 106: 21777-82.
44. Gallo V, Bueno-De-Mesquita HB, Vermeulen R, Andersen PM, Kyrozis A, Linseisen J. Smoking and risk for amyotrophic lateral sclerosis: analysis of the EPIC cohort. Ann Neurol. 2009; 65: 378-85.
45. Armon C. Smoking may be considered an established risk factor for sporadic ALS. Neurology. 2009; 73: 1693-8.
46. Armon C. An evidence-based medicine approach to the evaluation of the role of exogenous risk factors in sporadic amyotrophic lateral sclerosis. Neuroepidemiology. 2003; 22: 217-28.
47. Sutedja NA, Fischer K, Veldink JH, van der Heijden GJMG, Kromhout H, Heederik D, et al. What we truly know about occupation as a risk factor for ALS: a critical and systematic review. Amyotroph Lateral Scler. 2009; 10: 295-301.
48. Horner RD, Kamins KG, Feussner JR, Grambow SC, Hoff-Lidquist J, Harati Y, et al. Occurrence of amyotrophic lateral sclerosis among Gulf War veterans. Neurology. 2003; 61: 742-9.
49. Haley RW. Excess incidence of ALS in young Gulf War veterans. Neurology. 2003; 61: 750-6.
50. Chiò A, Benzi G, Dossena M, Mutani R, Mora G. Severely increased risk of amyotrophic lateral sclerosis among Italian professional football players. Brain. 2005; 128: 472-6.
51. Chio A, Calvo A, Dossena M, Ghiglione P, Mutani R, Mora G. ALS in Italian professional soccer players: the risk is still present and could be soccer-specific. Amyotroph Lateral Scler. 2009; 10: 205-9.
52. Hyams KC, Brown M, White DS. Resolving disputes about toxicological risks during military conflict: the US Gulf War experience. Toxicol Rev. 2005; 24: 167-80.
53. Armon C. Sports and trauma in amyotrophic lateral sclerosis revisited. J Neurol Sci. 2007; 262: 45-53.
54. Edwards IR, Star K, Kiuru A. Statins, neuromuscular degenerative disease and an amyotrophic lateral sclerosis-like syndrome: an analysis of individual case safety reports from vigibase. Drug Saf. 2007; 30: 515-25.
55. Colman E, Szarfman A, Wyeth J, Mosholder A, Jillapalli D, Levine J, et al. An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA's spontaneous adverse event reporting system. Pharmacoepidemiol Drug Saf. 2008; 17: 1068-76.
56. Dupuis L, Corcia P, Fergani A, et al. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology. 2008; 70: 1004-9.
57. Keizman D, Ish-Shalom M, Berliner S, Maimon N, Vered Y, Artamonov I, et al. Low uric acid levels in serum of patients with ALS: further evidence for oxidative stress? J Neurol Sci. 2009; 285: 95-9.
58. Jawaid A, Salamone AR, Strutt AM, Murthy SB, Wheaton M, McDowell EJ et al. ALS disease onset may occur later in patients with pre-morbid diabetes mellitus. Eur J Neurol 2010 Epub.
59. Bruijn LI, Becher MW, Lee MK, Anderson KL, Jenkins NA, Copeland NG, et al. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron. 1997; 18: 327-38.
60. Gurney ME, Pu H, Chiu AY, DalCanto MC, Polchow CY, Alexander DD, et al. Motor neuron degeneration in mice that express human Cu, Zn superoxide dismutase mutation. Science. 1994; 264: 1772-5.
61. Wong PC, Pardo CA, Borchelt DR, Lee MK, Copeland NG, Jenkins NA, et al. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron. 1995; 14: 1105-16.
62. Bruijn LI, Houseweart MK, Kato S, Anderson KL, Anderson SD, Ohama E, et al. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science. 1998; 281: 1851-54.
63. Gong YH, Parsadanian AS, Andreeva A, et al. Restricted expression of G86R Cu/Zn superoxide dismutase in astrocytes results in astrocytosis but does not cause motoneuron degeneration. J Neurosci. 2000; 20: 660-5.
64. Pramatarova A, Laganiere J, Roussel J, Brisebois K, Rouleau GA. Neuron-specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor neuron impairment. J Neurosci. 2001; 21: 3369-74.
65. Lino MM, Schneider C, Caroni P. Accumulation of SOD1 mutant in postnatal motor neurons does not cause motor neuron pathology of motoneuron disease. J Neurosci. 2002; 22: 4825-32.
66. Clement AM, Nguyen MD, Roberts EA, Garcia ML, Boillee S, Rule M, et al. Wild-type nonneuronal cells extended survival of SOD1 mutant motor neurons in ALS mice. Science. 2003; 302: 113-7.
67. Nagai M, Re DB, Nagata T, Chalazonitis A, Jessell TM, Wichterle H, et al. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci. 2007; 10: 615-22.
68. Beers DR, Henkel JS, Xiao Q, Zhao W, Wang J, Yen AA, et al. Wild-type microglia extend survival in PU. 1 knockout mice with familial amyotrophic lateral sclerosis. Proc Natl Acad Sci. 2006; 103: 16021-6.
69. Boillee S, Yamanaka K, Lobsiger CS, Copeland NG, Jenkins NA, Kassiotis G, et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science. 2006; 312: 1389-92.
70. Yamanaka K, Chun SJ, Boillee S, Fujimori-Tonou N, Yamashita H, Gutmann DH, et al. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci. 2008; 11: 251-3.
71. Yamanaka K, Boillee S, Roberts EA, Garcia ML, McAlonis-Downes M, Mikse OR, et al. Mutant SOD1 in cell types other than motor neurons and oligodendrocytes accelerates onset of disease in ALS mice. Proc Natl Acad Sci. 2008; 105: 7594-9.
72. Spreux-Varoquaux O, Bensimon G, Lacomblez L, et al. Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a reappraisal using a new HPLC method with colometric detection in a large cohort of patients. J Neurol Sci. 2002; 193: 73-8.
73. Rothstein JD, van Kammen M, Levey AL, Martin LJ, Kuncl RW. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol. 1995; 38: 73-84.
74. Beal MF, Ferrante RJ, Browne SE, et al. Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann Neurol. 1997; 42: 644-54.
75. Arai T, Hasegawa M, Akiyama H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006; 35: 602-11.
76. Tan CF, Eguchi H, Tagawa A, et al. TDP-43 immunoreactivity in neuronal inclusions in familial amyotrophic lateral sclerosis with or without SOD1 gene mutation. Acta Neuropathol. 2007; 113: 535-42.
77. Shi P, Gal J, Kwinter DM, Liu X, Zhu H. Mitochondrial dysfunction in amyotrophic lateral sclerosis. Biochim Biophys Acta. 2010; 1802: 45-51.
78. Klivenyi P, Ferrante RJ, Matthews RT, et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med. 1999; 5: 347-50.
79. Rosenfeld J, King RM, Jackson CE, Bedlack RS, Barohn RJ, Dick A, et al. Creatine monohydrate in ALS: Effects on strength, fatigue, respiratory status and ALSFRS. Amyotroph Lateral Scler. 2008; 9: 266-72.
80. Bruijn LI, Miller TM, Cleveland DW. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci. 2004; 27: 723-49.
81. Rothstein JD. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol. 2009; 65: S3-9.
82. Qureshi M, Schoenfeld DA, Paliwal Y, Shui A, Cudkowicz ME. The natural history of ALS is changing: improved survival. Amyotroph Lateral Scler. 2009; 10: 324-31.
83. Cheah BC, Boland RA, Brodaty NE, Zoing MC, Jeffery SE, MacKenzie DK, et al. INSPIRATIonAL-INSPIRAtory muscle training in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2009; 10: 384-92.
84. Bourke SC, Tomlinson M, Williams TL, Bullock RE, Shaw PJ, Gibson GJ. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis. Lancet Neurol. 2006; 5: 140-57.
85. Heffernan C, Jenkinson C, Holmes T, Macleod H, Kinnear W, Oliver D, et al. Management of respiration in MND/ALS patients: an evidence-based review. Amyotroph Lateral Scler. 2006; 7: 5-15.
86. Carratu P, Spicuzza L, Cassano A, Maniscalco M, Gadaleta F, Lacedonia D, et al. Early treatment with noninvasive positive pressure ventilation prolongs survival in amyotrophic lateral sclerosis patients with nocturnal respiratory insufficiency. Orphanet J Rare Dis. 2009; 10: 4-10.
87. Radunovic A, Annane D, Jewitt K, Mustfa N. Mechanical ventilation for amyotrophic lateral sclerosis / motor neuron disease. Cochrane Database Syst Rev 2009.
88. Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, Johnston W, et al. Practice Parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review). Neurology. 2009; 73: 1218-26.
89. Onders RP, Elmo M, Khansarinia S, Bowman B, Yee J, Road J, et al. Complete world-wide operative experience in laparoscopic diaphragm pacing: results and differences in spinal cord injured patients and amyotrophic lateral sclerosis patients. Surg Endosc. 2009; 23: 1433-40.
90. Vaisman N, Lusaus M, Nefussy B, Niv E, Comaheshter D, Hallack R, et al. Do patients with amyotrophic lateral sclerosis (ALS) have increased energy needs? J Neurol Sci. 2009; 279: 26-9.
91. Funalot B, Desport JC, Sturtz F, Camu W, Couratier P. High metabolic level in patients with familial amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2009; 10: 113-7.
92. Daly JJ, Wolpaw JR. Brain-computer interfaces in neurological rehabilitation. Lancet Neurol. 2008; 7: 1032-43.
93. Drory VE, Goltsman E, Goldman Reznik J, Mosek A, Korczyn AD. The value of muscle exercise in patients with amyotrophic lateral sclerosis. J Neurol Sci. 2001; 191: 133-7.
94. Dal Bello-Haas VP, Florence JM, Kloos AD, et al. A randomized controlled trial of resistance exercise in individuals with ALS. Neurology. 2007; 68: 2003-7.
95. Traynor BJ, Alexander M, Corr B, Frost E, Hardiman O. Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996-2000. J Neurol Neurosurg Psychiatry. 2003; 74: 1258-61.
96. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med. 1994; 330: 585-91.
97. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet. 1996; 347: 1425-31.
98. Bellingham MC. A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade? CNS Neurosci Ther 2010 Epub.
99. Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2007: CD001447.
100. Stone CA, O'Leary N. Systematic review of the effectiveness of botulinum toxin or radiotherapy for sialorrhea in patients with amyotrophic lateral sclerosis. J Pain Symptom Manage. 2009; 37: 246-58.
101. Bedlack RS, Pastula DM, Hawes J, Heydt D. Open-label trial of levetiracetam for cramps and spasticity in patients with motor neuron disease. Amyotroph Lateral Scler. 2009; 10: 205-9.
102. Rabkin JG, Gordon PH, McElhiney M, Rabkin R, Chew S, Mitsumoto H. Modafinil treatment of fatigue in patients with ALS: a placebo-controlled study. Muscle Nerve. 2009; 39: 297-303.
103. Pascuzzi RM, Shefner J, Chappell AS, Bjerke JS, Tamura R, Chaudhry V, et al. A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010; 11: 266-71.
104. Lee SG, Emdad L, Gupta P, Sarkar D, Borjabad A, Volsky DJ, et al. Mechanism of ceftriaxone induction of excitatory amino acid transporter-2 expression and glutamate uptake in primary human astrocytes. J Biol Chem. 2008; 283: 13116-23.
105. Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, et al. β-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature. 2005; 433: 73-7.
106. Rosen H. Dextromethorphan/quinidine sulfate for pseudobulbar affect. Drugs Today. 2008; 44: 661-8.
107. Oosthuyse B, Moons L, Storkebaum E, Beck H, Nuyens D, Brusselmans K, et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet. 2001; 28: 131-8.
108. Wang Y, Mao XO, Xie L, Banwait S, Marti HH, Greenberg DA, et al. Vascular endothelial growth factor overexpression delays neurodegeneration and prolongs survival in amyotrophic lateral sclerosis mice. J Neurosci. 2007; 27: 304-7.
109. Azzouz M, Ralph GS, Storkebaum E, Walmsley LE, Mitrophanous KA, Kingsman SM, et al. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature. 2004; 429: 413-7.
110. Lambrechts D, Poesen K, Fernandez-Santiago R, Al-Chalabi A, Del Bo R, van Vught PW, et al. Meta-analysis of vascular endothelial growth factor variations in amyotrophic lateral sclerosis: increased susceptibility in male carriers of the-2578AA genotype. J Med Genet. 2009; 46: 840-6.
111. Lanka V, Wieland S, Barber J, Cudkowicz M. Arimoclomol: a potential therapy under development for ALS. Expert Opin Investig Drugs. 2009; 18: 1907-18.
112. Cudkowicz ME, Shefner JM, Simpson E, Grasso D, Yu H, Zhang H, et al. Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis. Muscle Nerve. 2008; 38: 837-44.
113. Gribkoff VK, Bozik ME. KNS-760704 [(6R)-4, 5, 6, 7-tetrahydro-N6-propyl-2, 6-benzothiazole-diamine dihydrochloride monohydrate] for the treatment of amyotrophic lateral sclerosis. CNS Neurosci Ther. 2008; 14: 215-28.
114. Bozik M, Ingersoll E, Volles L, Mather J, Amburgey C, Moritz J, et al. KNS-760704-CL201, part 1: a 12-week phase 2 study of the safety, tolerability, and clinical effects of KNS 760704 in ALS subjects. Amyotroph Lateral Scler. 2009; 10: S28-29.
115. Bordet T, Buisson B, Michaud M, Drouot C, Galea P, Delaage P, et al. Identification and characterization of cholest-4-en-3-one, oxime (RTO19622), a novel drug candidate for amyotrophic lateral sclerosis. J Pharmacol Exp Ther. 2007; 322: 709-20.
116. Xu L, Yan J, Chen D, Welsh AM, Hazel T, Johe K, et al. Human neuronal stem cells grafts ameliorate motor neuron disease in SOD-1 transgenic rats. Transplantation. 2006; 82: 865-75.
117. Martinez HR, Gonzales-Garza MT, Moreno-Cuevas JE, Caro E, Gutierrez-Jimenez E, Segura JJ. Stem-cell transplantation into the frontal motor cortex in amyotrophic lateral sclerosis patients. Cytotherapy. 2009; 11: 26-34.
118. Mazzini L, Ferrero I, Luparello V, Rustichelli D, Gunetti M, Mareschi K, et al. Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: a Phase I clinical trial. Exp Neurol. 2010; 223: 229-37.
119. Dimos JT, Rodolfa KT, Niakan KK, Weisenthal LM, Mitsumoto H, Chung W, et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science. 2008; 321: 1218-21.